全文获取类型
收费全文 | 26623篇 |
免费 | 2973篇 |
国内免费 | 1928篇 |
专业分类
耳鼻咽喉 | 154篇 |
儿科学 | 307篇 |
妇产科学 | 279篇 |
基础医学 | 2900篇 |
口腔科学 | 570篇 |
临床医学 | 3597篇 |
内科学 | 3562篇 |
皮肤病学 | 313篇 |
神经病学 | 1249篇 |
特种医学 | 968篇 |
外国民族医学 | 12篇 |
外科学 | 2423篇 |
综合类 | 5242篇 |
现状与发展 | 7篇 |
一般理论 | 2篇 |
预防医学 | 2102篇 |
眼科学 | 559篇 |
药学 | 2917篇 |
38篇 | |
中国医学 | 2321篇 |
肿瘤学 | 2002篇 |
出版年
2024年 | 142篇 |
2023年 | 559篇 |
2022年 | 1401篇 |
2021年 | 1721篇 |
2020年 | 1390篇 |
2019年 | 1020篇 |
2018年 | 1060篇 |
2017年 | 1038篇 |
2016年 | 883篇 |
2015年 | 1279篇 |
2014年 | 1562篇 |
2013年 | 1387篇 |
2012年 | 2001篇 |
2011年 | 2066篇 |
2010年 | 1386篇 |
2009年 | 1139篇 |
2008年 | 1186篇 |
2007年 | 1295篇 |
2006年 | 1130篇 |
2005年 | 1021篇 |
2004年 | 891篇 |
2003年 | 1063篇 |
2002年 | 955篇 |
2001年 | 790篇 |
2000年 | 522篇 |
1999年 | 458篇 |
1998年 | 303篇 |
1997年 | 332篇 |
1996年 | 243篇 |
1995年 | 214篇 |
1994年 | 174篇 |
1993年 | 101篇 |
1992年 | 170篇 |
1991年 | 124篇 |
1990年 | 77篇 |
1989年 | 88篇 |
1988年 | 72篇 |
1987年 | 73篇 |
1986年 | 51篇 |
1985年 | 40篇 |
1984年 | 33篇 |
1983年 | 19篇 |
1982年 | 17篇 |
1981年 | 13篇 |
1980年 | 10篇 |
1979年 | 12篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
11.
Xiaojie Wu Leyan Zhang Jiadi Zhou Luying Liu Qiang Fu Aili Fu Xiaoying Feng Rui Xin Hongrui Liu Yong Gao Jiangnan Xue 《Current problems in cancer》2019,43(1):18-26
Aim
Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an immune inhibitory receptor which is expressed within most types of hematopoietic cells and negatively regulates immune responses. Recently, we found LAIR-1 expression to be present within tumors of nonhematopoietic lineages. However, the roles of LAIR-1 in hepatocellular carcinoma (HCC) have yet to be examined. The purpose of this study was to investigate the expression of LAIR-1 in HCC tissue and assess its clinical significance at this site.Materials and methods
Expression levels of LAIR-1 within HCC samples collected from 90 patients and compared with that of slides of normal liver tissue collected from 9 non-HCC patients were measured by immunohistochemistry using tissue microarrays. A semiquantitative score was assigned, as was based on staining intensity and percent of positive cells and a Spearman Rank correlation test was used to assess any potential significant correlations between LAIR-1 expression and clinicopathological factors. Overall survival analysis was performed using the Kaplan-Meier and Log Rank statistical test.Results
LAIR-1 expression was detected in cancer tissue and adjacent tumor tissue, but not in normal liver tissue. The percent of LAIR-1-positive expression in cancer tissue of HCC samples was 97.78% (88/90) while that in adjacent tumor tissue was 96.67% (87/90). Significantly greater expression levels of LAIR-1 were obtained from cancer tissue (Mean?±?SD?=?5.722?±?2.145) than that in adjacent tumor tissue (4.141?±?1.486). In addition, LAIR-1 expression was found to be significantly correlated with pathological grade of HCC, T stage, and age. Expression levels of LAIR-1 were related with worse overall survival rates of HCC patients, especially in HCC patients with hepatic cirrhosis.Conclusion
Results of this study show that LAIR-1 is expressed in HCC tissues and that high levels of LAIR-1 expression are associated with the poor cancer differentiation. In addition, overexpression of LAIR-1 was significantly associated with worse overall survival in the patients with HCC. These data suggest that LAIR-1 may be an independent predictor for clinical outcomes in patients with HCC. 相似文献12.
目的 前瞻性评估T1~T2期乳腺癌保乳术后化疗后程大分割放疗的不良反应和耐受性,以及在缩短治疗时间、减轻患者经济负担等方面的价值。方法 共入组20例T1~T2期乳腺癌保乳术后患者,所有患者于末次多西他赛化疗前开始大分割放疗。观察急性放射反应、治疗完成率及无病生存率、住院时间及住院费用等。结果 治疗完成率100%。主要不良反应为血液学毒性(白细胞减少)及皮肤反应,患者均可耐受。中位随访时间为30.1个月,随访率100%。美容效果良好率100%。平均总治疗时间为4周,总住院治疗费用节省约1万元。21个月无病生存率为100%。结论 T1~T2期乳腺癌保乳术后可耐受同步大分割放化疗,局部控制好,美容效果佳,且具有较高的卫生经济学价值。 相似文献
13.
14.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
15.
16.
High-pressure injection injuries (HPII) caused by water swelling sealant are rare at present. The patient generally has small-sized skin lesions, and the misleadingly benign presentation may cause delayed treatment at the early stage of management. In addition, radiographic examination may be underestimated. Subsequently, the inadequate surgical intervention may cause tissue necrosis and poor prognosis. Furthermore, the early recognition of water swelling sealant injected into tissue and emergent surgical intervention are the key to successful management for the patient with HPII caused by injecting water swelling sealant to tissue. 相似文献
17.
18.
19.
20.
目的对比研究腹腔镜下外生性肾血管平滑肌脂肪瘤"蘑菇状"剜除与标准肾部分切除术的安全性及有效性,为肾血管平滑肌脂肪瘤腹腔镜下"蘑菇状"剜除术术式的建立提供临床依据。
方法选取海南医学院第二附属医院与解放军总医院2018年1月至2019年5月期间,接受腹腔镜手术的肾血管平滑肌脂肪瘤患者53例,其中25例沿肿瘤假包膜行"蘑菇状"剜除术(A组)、28例行肾部分切除术(B组)。比较两组手术患者的肾动脉阻断时间、手术时间、术中出血量、术后24 h血红蛋白、术后eGFR(estimated glomerular filtration rate,估计肾小球率过滤)的变化、术后住院时间和术后肿瘤复发率。
结果53例手术无术中转开放,无死亡病例。肾动脉阻断时间:A组(11.9±2.2)min、B组(21.5±6.5) min(P<0.001)。手术时间:A组(87.9±24.8)min、B组(114.3±38.9) min(P<0.001)。术中出血量:A组20 ml(20~40)ml、B组50 ml(50~100)ml(P<0.001)。术后24 h血红蛋白变化:A组(7.4±4.3) g/L、B组(12.4±8.8) g/L(P=0.013)。术后24 h eGFR变化:A组(6.2±7.2 )ml(min·1.73 m2),B组(12.7±12.8)ml(min·1.73 m2)(P=0.027)。术后6个月eGFR变化:A组(1.5±3.7)ml(min·1.73 m2)、B组(6.5±5.6)ml(min·1.73 m2)(P<0.001)。术后住院时间:A组4.0 d(3~4)d、B组4.5 d(3~6)d(P=0.023)。术后随访两组术后肿瘤均无复发。
结论采用腹腔镜"蘑菇状"剜除术治疗外生性肾血管平滑肌脂肪瘤在肾动脉阻断时间、术中出血量、术后24 h血红蛋白、术后eGFR变化、术后住院时间等方面均优于传统肾部分切除术,两组术后肿瘤均无复发;该方法安全、有效,适于临床推广。 相似文献